Apr. 2, 2026
MetaTrim BHB Supplement Faces Scrutiny Over Keto Claims
Exogenous Ketone Formula Touts Quick Metabolic Boost, But Research Suggests Limitations
Apr. 1, 2026
FDA Approves New Obesity Pill Foundayo, Offering Patients Another Option
The daily pill from Eli Lilly will compete with Wegovy's pill form as an alternative to injectable obesity drugs.
Apr. 1, 2026
FDA Approves Eli Lilly's New Weight Loss Pill
Foundayo, a GLP-1 drug, is the second daily oral medication for obesity treatment in the U.S.
Apr. 1, 2026
Ambrosia Raises $100M to Develop Small Molecule GLP-1 Drugs
Colorado biotech aims to unlock next stage of obesity treatments with oral GLP-1 agonists.
Apr. 1, 2026
Ambrosia Raises $100M for Next-Gen Small Molecule GLP-1 Drugs
The Colorado biotech aims to surpass first-generation oral GLP-1 pills with its AI-powered molecule design platform.
Apr. 1, 2026
FDA Approves Eli Lilly's New Weight-Loss Pill for Obesity
The oral medication Foundayo is the second daily pill for treating obesity and weight-related conditions.
Apr. 1, 2026
FDA Approves Eli Lilly's Oral GLP-1 Weight Loss Pill Foundayo
The new medication offers patients more flexibility in their treatment approach.
Apr. 1, 2026
FDA Approves Eli Lilly's New Weight-Loss Pill
The drug is the second daily oral medication approved to treat obesity and related conditions.
Apr. 1, 2026
GLP-1 Drugs Driving Two Types of Consumers
Weight loss medications create distinct demands around indulgence and functionality, says Sprinkles Cupcakes founder.
Apr. 1, 2026
Weight Watchers Expands Wegovy Savings for Members
New partnership with Novo Nordisk offers up to $1,200 annual savings on FDA-approved weight loss medication.
Apr. 1, 2026
Federal Court Dismisses Maine Weight Loss Drug Lawsuits
Appeals court sides with insurance companies in cases alleging discrimination against those diagnosed with obesity
Mar. 31, 2026
Nourish Medication Shows Strong Six-Month Persistence
New data reveals GLP-1 drug outperforms industry benchmarks for patient adherence.
Mar. 31, 2026
Kentucky Man Warns of Dangers in Unregulated Weight-Loss Drug Market
Jimmie Wilson's near-fatal experience with a compounded GLP-1 medication highlights the risks of the booming but loosely regulated weight-loss drug industry.
Mar. 31, 2026
Ambrosia Bio raises $100M for oral GLP-1 trial
The funding will support clinical trials for the company's oral weight loss drug candidate.
Mar. 31, 2026
MediRX expands digital healthcare platform nationwide
Leading GLP-1 treatment provider brings accessible weight management solutions to patients across the U.S.
Mar. 30, 2026
The 'Metabolic Lock' Affecting Women Over 40
New research reveals why diet and exercise stop working after a certain age.
Mar. 30, 2026
Allergan Aesthetics Presents New Data on Neurotoxin and Weight Loss Aesthetics at AAD Meeting
Findings highlight safety and efficacy of investigational TrenibotE and insights on growing GLP-1 agonist patient population seeking aesthetic treatments.
Mar. 30, 2026
Doctor Loses 125lbs, Reverses Type 2 Diabetes
Kevin Gendreau, MD, transformed his health through diet, exercise, and a renewed sense of purpose.
Mar. 30, 2026
New Citrus Supplement Targets 'Metabolic Lock' After 40
CitrusBurn formula uses polyphenols to re-engage natural fat-burning signals without jitters or crashes.
Mar. 30, 2026
GLP-1 Drugs Emerge as Popular Weight Loss Option
Brown University professor Dr. Emily Oster discusses the impact of GLP-1 medications on weight loss.
